Zogenix (ZGNX) Reports Q2 EPS of $3.78

Zogenix (NASDAQ: ZGNX) reported Q2 EPS of $3.78, versus $3.59 reported last year. Revenue for the quarter came in at $7.4 million versus the consensus estimate of $5.13 million.

"With further positive data from the Belgian study of low-dose fenfluramine in Dravet syndrome, a clear development path for Phase 3 that now includes significant input from the FDA and the successful execution of a Dravet syndrome-focused KOL event, we have generated significant momentum over the past several months," said Stephen J. Farr, Ph.D., President and CEO. "From a clinical development standpoint, we are well-positioned to begin our Phase 3 program for ZX008 in the fourth quarter of 2015. In addition, following our recent capital raise, Zogenix is now in the strongest financial position in our company's history, and our cash should be sufficient to take us through the regulatory submissions, and potential approvals, of ZX008 in the U.S. and Europe."

For earnings history and earnings-related data on Zogenix (ZGNX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49